FILING ANALYSIS · MONDAY, NOVEMBER 2
NEUROCRINE BIOSCIENCES INC NBIX — 8-K: Results of Operations and Financial Condition
positive
Neurocrine Biosciences' Q3 revenue grew 41% year-over-year to $1.1 billion, with INGREZZA net product sales increasing 17% to $801 million, and the company raised its full-year 2026 guidance for INGREZZA sales to $2.9-2.925 billion. The strong financial results and increased guidance are positive surprises.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →